{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:59:03Z","timestamp":1780325943890,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to nutritional stimuli leading to pancreatic insulin secretion and suppression of glucagon release. GLP-1 further inhibits gastric motility and reduces appetite which in conjunction improves postprandial glucose metabolism. Additional vasoprotective effects have been described for GLP-1 in experimental models. Despite these vasoprotective actions, associations between endogenous levels of GLP-1 and cardiovascular disease have yet not been investigated in humans which was the aim of the present study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>GLP-1 serum levels were assessed in a cohort of 303 patients receiving coronary CT-angiography due to typical or atypical chest pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>GLP-1 was found to be positively associated with total coronary plaque burden in a fully adjusted model containing age, sex, BMI, hypertension, diabetes mellitus, smoking, triglycerides, LDL-C (low density lipoprotein cholesterol), hsCRP (high-sensitive C-reactive protein), and eGFR (estimated glomerular filtration rate) (OR: 2.53 (95% CI: 1.12 \u2013 6.08; p\u2009=\u20090.03).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Circulating GLP-1 was found to be positivity associated with coronary atherosclerosis in humans. The clinical relevance of this observation needs further investigations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1475-2840-12-117","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T16:18:41Z","timestamp":1376669921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans"],"prefix":"10.1186","volume":"12","author":[{"given":"Katja","family":"Piotrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zugwurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Biller-Friedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Spoettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger P","family":"Laubender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Lebherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Goeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"issue":"9","key":"705_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"SR Seshasai","year":"2011","unstructured":"Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011, 364 (9): 829-841.","journal-title":"N Engl J Med"},{"issue":"7","key":"705_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2337\/diacare.25.7.1135","volume":"25","author":"E Bonora","year":"2002","unstructured":"Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002, 25 (7): 1135-1141. 10.2337\/diacare.25.7.1135.","journal-title":"Diabetes Care"},{"key":"705_CR3","doi-asserted-by":"publisher","first-page":"d4169","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011, 343: d4169-10.1136\/bmj.d4169.","journal-title":"BMJ"},{"issue":"3","key":"705_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1900\/RDS.2011.8.382","volume":"8","author":"M Lehrke","year":"2011","unstructured":"Lehrke M, Marx N: Cardiovascular effects of incretin-based therapies. Rev Diabet Stud. 2011, 8 (3): 382-391. 10.1900\/RDS.2011.8.382.","journal-title":"Rev Diabet Stud"},{"issue":"6","key":"705_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132 (6): 2131-2157. 10.1053\/j.gastro.2007.03.054.","journal-title":"Gastroenterology"},{"issue":"3","key":"705_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","volume":"50","author":"T Vilsboll","year":"2001","unstructured":"Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001, 50 (3): 609-613. 10.2337\/diabetes.50.3.609.","journal-title":"Diabetes"},{"issue":"6","key":"705_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gut.38.6.916","volume":"38","author":"LR Ranganath","year":"1996","unstructured":"Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V: Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut. 1996, 38 (6): 916-919. 10.1136\/gut.38.6.916.","journal-title":"Gut"},{"issue":"4","key":"705_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1530\/eje.0.1350425","volume":"135","author":"AA Vaag","year":"1996","unstructured":"Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB: Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)\u2013evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol. 1996, 135 (4): 425-432. 10.1530\/eje.0.1350425.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"705_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","volume":"56","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, Knop FK: Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013, 56 (5): 965-972. 10.1007\/s00125-013-2841-0. Epub 2013 Feb 3","journal-title":"Diabetologia"},{"key":"705_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2840-9-17","volume":"9","author":"M Yamaoka-Tojo","year":"2010","unstructured":"Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010, 9: 17-10.1186\/1475-2840-9-17.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"705_CR11","doi-asserted-by":"publisher","first-page":"e4733","DOI":"10.1371\/journal.pone.0004733","volume":"4","author":"UC Broedl","year":"2009","unstructured":"Broedl UC, Lebherz C, Lehrke M, Stark R, Greif M, Becker A, von Ziegler F, Tittus J, Reiser M, Becker C: Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One. 2009, 4 (3): e4733-10.1371\/journal.pone.0004733.","journal-title":"PLoS One"},{"key":"705_CR12","first-page":"215764","volume":"2011","author":"M Monami","year":"2011","unstructured":"Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, Marchionni N, Mannucci E: Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011, 2011: 215764.","journal-title":"Exp Diabetes Res"},{"issue":"2","key":"705_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.12000","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami M, Ahren B, Dicembrini I, Mannucci E: Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013, 15 (2): 112-120. 10.1111\/dom.12000.","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"705_CR14","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","volume":"124","author":"Z Shah","year":"2011","unstructured":"Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011, 124 (21): 2338-2349. 10.1161\/CIRCULATIONAHA.111.041418.","journal-title":"Circulation"},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2840-11-107","volume":"11","author":"Y Fujishima","year":"2012","unstructured":"Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012, 11: 107-10.1186\/1475-2840-11-107.","journal-title":"Cardiovasc Diabetol"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1475-2840-11-142","volume":"11","author":"CJ Li","year":"2012","unstructured":"Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol. 2012, 11: 142-10.1186\/1475-2840-11-142.","journal-title":"Cardiovasc Diabetol"},{"key":"705_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1475-2840-11-64","volume":"11","author":"AS Kelly","year":"2012","unstructured":"Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012, 11: 64-10.1186\/1475-2840-11-64.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"705_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ajpath.2012.07.015","volume":"181","author":"NA Gupta","year":"2012","unstructured":"Gupta NA, Kolachala VL, Jiang R, Abramowsky C, Romero R, Fifadara N, Anania F, Knechtle S, Kirk A: The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol. 2012, 181 (5): 1693-1701. 10.1016\/j.ajpath.2012.07.015.","journal-title":"Am J Pathol"},{"issue":"11","key":"705_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.2513","volume":"17","author":"H Ellingsgaard","year":"2011","unstructured":"Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD: Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011, 17 (11): 1481-1489. 10.1038\/nm.2513.","journal-title":"Nat Med"},{"issue":"1","key":"705_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2008.08.036","volume":"204","author":"VF Panoulas","year":"2009","unstructured":"Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, Nightingale P, Kitas GD: Association of interleukin-6 (IL-6)-174G\/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009, 204 (1): 178-183. 10.1016\/j.atherosclerosis.2008.08.036.","journal-title":"Atherosclerosis"},{"issue":"3","key":"705_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","volume":"53","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B: Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004, 53 (3): 654-662. 10.2337\/diabetes.53.3.654.","journal-title":"Diabetes"},{"issue":"2","key":"705_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jc.74.2.379","volume":"74","author":"C Orskov","year":"1992","unstructured":"Orskov C, Andreasen J, Holst JJ: All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab. 1992, 74 (2): 379-384. 10.1210\/jc.74.2.379.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"705_CR23","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1210\/jc.2008-1296","volume":"94","author":"R Abu-Hamdah","year":"2009","unstructured":"Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009, 94 (6): 1843-1852. 10.1210\/jc.2008-1296.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"705_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007, 298 (3): 309-316. 10.1001\/jama.298.3.309.","journal-title":"JAMA"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-12-117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:14:10Z","timestamp":1630545250000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-12-117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,16]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-12-117","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,16]]},"assertion":[{"value":"29 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"117"}}